Article
Multidisciplinary Sciences
Mari Tone, Kota Iwahori, Takayuki Shiroyama, Shinji Futami, Yujiro Naito, Kiyoharu Fukushima, Kotaro Miyake, Shohei Koyama, Haruhiko Hirata, Izumi Nagatomo, Hisashi Wada, Yoshito Takeda, Atsushi Kumanogoh
Summary: Minocycline administration in NSCLC patients treated with first-line EGFR-TKIs was found to correlate with longer PFS and OS, independent of skin rash. This retrospective analysis suggests that minocycline may have a positive impact on the treatment outcomes of EGFR-mutant NSCLC patients.
SCIENTIFIC REPORTS
(2023)
Article
Cell Biology
Carolien Eggermont, Philippe Giron, Maxim Noeparast, Hugo Vandenplas, Pedro Aza-Blanc, Gustavo J. Gutierrez, Jacques De Greve
Summary: In this study, a high-throughput siRNA kinome screen was performed to identify targets involved in functional drug tolerance against EGFR TKI in NSCLC. STYK1 was identified as a potential target that, when downregulated, enhances the effects of EGFR inhibition. The study also found that STYK1 selectively interacts with mutant EGFR and that its downregulation counteracts the upregulation of FGF1 induced by EGFR TKI. Co-targeting EGFR and STYK1 could lead to a better overall outcome for NSCLC patients.
CELL DEATH & DISEASE
(2022)
Article
Medicine, Research & Experimental
Dan Yan, Justus M. Huelse, Dmitri Kireev, Zikang Tan, Luxiao Chen, Subir Goyal, Xiaodong Wang, Stephen Frye, Madhusmita Behera, Frank Schneider, Suresh S. Ramalingam, Taofeek Owonikoko, H. Shelton Earp, Deborah DeRyckere, Douglas K. Graham
Summary: Acquired resistance is inevitable in non-small cell lung cancers (NSCLCs) treated with osimertinib (OSI). Activation of MERTK is associated with OSI resistance and inhibition of MERTK kinase can resensitize resistant cells to OSI.
JOURNAL OF CLINICAL INVESTIGATION
(2022)
Article
Biochemistry & Molecular Biology
Ji Hye Kim, Jongwook Kim, Se Seul Im, Ji Hyeon Lee, Sein Hwang, Eun-Ju Chang, Dong-Myung Shin, Jin Kyung Rho, Jaekyoung Son
Summary: The research found that BIX induces apoptotic cell death in EGFR-mutant NSCLC cells and inhibits EGFR signaling, especially in EGFR-TKI resistant cells.
EXPERIMENTAL AND MOLECULAR MEDICINE
(2021)
Article
Oncology
Mengzhao Wang, James Chih-Hsin Yang, Paul L. Mitchell, Jian Fang, D. Ross Camidge, Weiqi Nian, Chao-Hua Chiu, Jianying Zhou, Yanqiu Zhao, Wu-Chou Su, Tsung-Ying Yang, Viola W. Zhu, Michael Millward, Yun Fan, Wen-Tsung Huang, Ying Cheng, Liyan Jiang, Daniel Brungs, Lyudmila Bazhenova, Chee Khoon Lee, Bo Gao, Yan Xu, Wei-Hsun Hsu, Li Zheng, Pasi A. Janne
Summary: This article reports the discovery and early clinical development of Sunvozertinib (DZD9008), a potential treatment option for EGFRexon20ins NSCLC.
Article
Multidisciplinary Sciences
Dongliang Bian, Liangdong Sun, Junjie Hu, Liang Duan, Haoran Xia, Xinsheng Zhu, Fenghuan Sun, Lele Zhang, Huansha Yu, Yicheng Xiong, Zhida Huang, Deping Zhao, Nan Song, Jie Yang, Xiao Bao, Wei Wu, Jie Huang, Wenxin He, Yuming Zhu, Gening Jiang, Peng Zhang
Summary: This study aimed to assess the feasibility of neoadjuvant Afatinib treatment for stage III NSCLC patients. The results showed that Afatinib improved the objective response rate (ORR) in NSCLC patients and caused dynamic changes in the tumor microenvironment.
NATURE COMMUNICATIONS
(2023)
Article
Biochemistry & Molecular Biology
Tao Jiang, Pingyang Wang, Jie Zhang, Yanqiu Zhao, Jianying Zhou, Yun Fan, Yongqian Shu, Xiaoqing Liu, Helong Zhang, Jianxing He, Guanghui Gao, Xiaoqian Mu, Zhang Bao, Yanjun Xu, Renhua Guo, Hong Wang, Lin Deng, Ningqiang Ma, Yalei Zhang, Hui Feng, Sheng Yao, Jiarui Wu, Luonan Chen, Caicun Zhou, Shengxiang Ren
Summary: This study investigated the efficacy and predictive biomarkers of toripalimab plus chemotherapy in EGFR-mutant advanced NSCLC patients as second-line treatment. The combination therapy showed promising anti-tumor activity with acceptable safety profiles, and DSPP mutation might serve as a potential biomarker for this combination. Further phase-III trials are ongoing to compare toripalimab versus placebo in this setting.
SIGNAL TRANSDUCTION AND TARGETED THERAPY
(2021)
Article
Medicine, Research & Experimental
Shigeki Nanjo, Wei Wu, Niki Karachaliou, Collin M. Blakely, Junji Suzuki, Yu-Ting Chou, Siraj M. Ali, D. Lucas Kerr, Victor R. Olivas, Jonathan Shue, Julia Rotow, Manasi K. Mayekar, Franziska Haderk, Nilanjana Chatterjee, Anatoly Urisman, Jia Chi Yeo, Anders J. Skanderup, Aaron C. Tan, Wai Leong Tam, Oscar Arrieta, Kazuyoshi Hosomichi, Akihiro Nishiyama, Seiji Yano, Yuriy Kirichok, Daniel S. W. Tan, Rafael Rosell, Ross A. Okimoto, Trever G. Bivona
Summary: This study investigates the impact of co-occurring genetic alterations on mutant EGFR and identifies the deficiency of RNA-binding factor RBM10 as a factor that decreases the efficacy of EGFR inhibitors in lung cancer treatment. The study reveals that RBM10 modulates tumor cell apoptosis by regulating the alternative splicing of Bcl-x and its deficiency diminishes EGFR inhibitor-mediated apoptosis. The findings suggest that co-occurring genetic alterations and splicing factor deficiency play a role in determining the sensitivity to targeted kinase inhibitor therapy.
JOURNAL OF CLINICAL INVESTIGATION
(2022)
Article
Oncology
Qing Zhou, Lin Wu, Pei Hu, Tongtong An, Jianying Zhou, Li Zhang, Xiao-Qing Liu, Feng Luo, Xin Zheng, Ying Cheng, Nong Yang, Junling Li, Jifeng Feng, Baohui Han, Yong Song, Kai Wang, Jian Fang, Hong Zhao, Yongqian Shu, Xiao-Yan Lin, Zhihong Chen, Bin Gan, Wan-Hong Xu, Wei Tang, Xiaoying Zhang, Jin-Ji Yang, Xiao Xu, Yi-Long Wu
Summary: Abivertinib at a dose of 300 mg twice a day demonstrated favorable clinical efficacy with manageable side effects in patients with EGFR T790M(+) NSCLC.
CLINICAL CANCER RESEARCH
(2022)
Article
Biochemistry & Molecular Biology
Yueqin Wang, Jingyao Wei, Luyao Feng, Ouwen Li, Lan Huang, Shaoxuan Zhou, Yingjie Xu, Ke An, Yu Zhang, Ruiying Chen, Lulu He, Qiming Wang, Han Wang, Yue Du, Ruijuan Liu, Chunmin Huang, Xiaojian Zhang, Yun-gui Yang, Quancheng Kan, Xin Tian
Summary: The study found that RNA methylation modification m(5)C and NSUN2 are significantly correlated with drug resistance in EGFR-mutant non-small-cell lung cancer. Overexpression of NSUN2 leads to gefitinib resistance and tumor recurrence, while genetic inhibition of NSUN2 results in tumor regression and overcomes intrinsic resistance to gefitinib. The study also reveals that NSUN2 promotes the translation of QSOX1 gene through methylation, mediating intrinsic resistance to gefitinib in EGFR-mutant non-small-cell lung cancer.
Article
Multidisciplinary Sciences
Chia- Shen, Heng-Sheng Chao, Tsu-Hui Shiao, Chi-Lu Chiang, Hsu-Ching Huang, Yung-Hung Luo, Chao-Hua Chiu, Yuh-Min Chen
Summary: In EGFR-mutant NSCLC patients, ICIs combined with chemotherapy may be more effective than ICIs alone. The T790M mutation may serve as a potential biomarker for treatment efficacy in these patients.
SCIENTIFIC REPORTS
(2021)
Article
Oncology
Hyun Ae Jung, Jinyeong Lim, Yoon-La Choi, Se-Hoon Lee, Je-Gun Joung, Yeong Jeong Jeon, Jae Won Choi, Sumin Shin, Jong Ho Cho, Hong Kwan Kim, Yong Soo Choi, Jae Ill Zo, Young Mog Shim, Sehhoon Park, Jong-Mu Sun, Jin Seok Ahn, Myung-Ju Ahn, Joungho Han, Woong-Yang Park, Jhingook Kim, Keunchil Park
Summary: This study aimed to identify risk factors for recurrence-free survival in early-stage EGFR-M+ non-small cell lung cancer patients and suggest personalized adjuvant strategies. Clinicopathologic and molecular risk factors were analyzed, and different treatment recommendations were provided for patients in different risk groups.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Alexis B. Cortot, Anne Madroszyk, Etienne Giroux-Leprieur, Olivier Molinier, Elisabeth Quoix, Henri Berard, Josiane Otto, Isabelle Rault, Denis Moro-Sibilot, Judith Raimbourg, Elodie Amour, Franck Morin, Jose Hureaux, Lionel Moreau, Didier Debieuvre, Hugues Morel, Aldo Renault, Eric Pichon, Benjamin Huret, Sandrine Charpentier, Marc G. Denis, Jacques Cadranel
Summary: The addition of cetuximab to afatinib in the treatment of treatment-naive advanced EGFR-mutant NSCLC did not show any significant improvement in efficacy, suggesting that further investigation into this combination therapy may not be warranted.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
R. B. Verheijen, T. T. van Duijl, M. M. van den Heuvel, D. Vessies, M. Muller, J. H. Beijnen, J. M. Janssen, J. H. M. Schellens, N. Steeghs, D. van den Broek, A. D. R. Huitema
Summary: EGFR mutations in circulating tumor DNA were quantified in 249 plasma samples from 68 NSCLC patients, showing driver mutations increased in copy number several months before disease progression. Quantification of EGFR mutations in plasma ctDNA was predictive of treatment outcomes in NSCLC patients, particularly an increase in driver mutation copy number could predict disease progression.
CANCER CHEMOTHERAPY AND PHARMACOLOGY
(2021)
Article
Oncology
Ciric To, Tyler S. Beyett, Jaebong Jang, William W. Feng, Magda Bahcall, Heidi M. Haikala, Bo H. Shin, David E. Heppner, Jaimin K. Rana, Brittaney A. Leeper, Kara M. Soroko, Michael J. Poitras, Prafulla C. Gokhale, Yoshihisa Kobayashi, Kamal Wahid, Kari J. Kurppa, Thomas W. Gero, Michael D. Cameron, Atsuko Ogino, Mierzhati Mushajiang, Chunxiao Xu, Yanxi Zhang, David A. Scott, Michael J. Eck, Nathanael S. Gray, Pasi A. Janne
Summary: Researchers have discovered a new EGFR inhibitor, JBJ-09-063, which shows efficacy against therapy-resistant mutations in EGFR-mutant lung cancer. The study also found that the resistance to JBJ-09-063 is caused by EGFR homo- or heterodimerization and specific mutations.
Article
Oncology
Mark W. Youngblood, Anh N. Tran, Wenxia Wang, Shejuan An, Denise Scholtens, Lyndsee Zhang, Kaitlyn O'Shea, Jenny L. Pokorny, Stephen T. Magill, Sean Sachdev, Rimas Lukas, Atique Ahmed, Dusten Unruh, Jordain Walshon, Kathleen McCortney, Yufen Wang, Aneta Baran, Felix Sahm, Kenneth Aldape, James P. Chandler, C. David James, Amy B. Heimberger, Craig Horbinski
Summary: This study identified 981 genes whose methylation was related to the progression-free survival of meningiomas. The molecular pathways associated with these genes were cross-referenced with FDA-approved cancer drugs, and Docetaxel was identified as a promising candidate. Docetaxel inhibited the growth of meningioma cells and enhanced radiation therapy, increasing apoptosis and extending survival in mouse models.
Article
Oncology
Hong-xia Tian, Zhi-hong Chen, Guang-Ling Jie, Zhen Wang, Hong-hong Yan, Si-pei Wu, Shui-lian Zhang, Dan-xia Lu, Xu-chao Zhang, Yi-long Wu
Summary: This study investigated the characteristics and prognostic features of the NF1 gene in EGFR mutant lung cancer patients. The results showed that NF1 mutations were enriched in older, male, and smoking patients, and were mutually exclusive with TP53, BRAF, and RASA1 mutations. TP53 mutation worsened the prognosis in cases of NF1 mutant or EGFR/NF1 co-mutant lung adenocarcinomas. NF1 mutations were not associated with overall survival in lung adenocarcinoma patients, but NF1/EGFR co-mutation patients had a longer overall survival than those with a single mutation of either gene. Furthermore, NF1 mutations significantly prolonged overall survival in EGFR mutant/TP53 wild-type patients but not in patients with EGFR/TP53 co-mutations.
Article
Oncology
Gilberto de Castro Jr, Iveta Kudaba, Yi-Long Wu, Gilberto Lopes, Dariusz M. Kowalski, Hande Z. Turna, Christian Caglevic, Li Zhang, Boguslawa Karaszewska, Konstantin K. Laktionov, Vichien Srimuninnimit, Igor Bondarenko, Kaoru Kubota, Rinee Mukherjee, Jianxin Lin, Fabricio Souza, Tony S. K. Mok, Byoung Chul Cho
Summary: This study presented the 5-year results of the KEYNOTE-042 trial, which showed that pembrolizumab demonstrated long-term clinical benefit compared to chemotherapy in patients with PD-L1-positive, locally advanced/metastatic non-small-cell lung cancer. Regardless of the level of PD-L1 expression, pembrolizumab had a better overall survival rate, confirming its status as a standard of care for this patient population.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Parneet Cheema, Byoung Chul Cho, Helano Freitas, Mariano Provencio, Yuh Min Chen, Sang-We Kim, Yi-Long Wu, Antonio Passaro, Claudio Martin, Marcello Tiseo, Gee-Chen Chang, Keunchil Park, Benjamin Solomon, Otto Burghuber, Janessa Laskin, Ziping Wang, Sung Yong Lee, Yanping Hu, Johan Vansteenkiste, He-long Zhang, Emer Hanrahan, Thomas Geldart, Rosemary Taylor, Leslie Servidio, Jingyi Li, Filippo de Marinis
Summary: This study reports the final analysis from ASTRIS, the largest real-world study of osimertinib in patients with advanced/metastatic EGFR T790M NSCLC. The results demonstrate the clinical benefit and safety of osimertinib in this patient population.
Article
Oncology
Roy S. Herbst, Yi-Long Wu, Thomas John, Christian Grohe, Margarita Majem, Jie Wang, Terufumi Kato, Jonathan W. Goldman, Konstantin Laktionov, Sang-We Kim, Chong-Jen Yu, Huu Vinh Vu, Shun Lu, Kye Young Lee, Guzel Mukhametshina, Charuwan Akewanlop, Filippo de Marinis, Laura Bonanno, Manuel Domine, Frances A. Shepherd, Damien Urban, Xiangning Huang, Ana Bolanos, Marta Stachowiak, Masahiro Tsuboi
Summary: The study demonstrates that adjuvant osimertinib provides a prolonged disease-free survival (DFS) benefit, reduces the risk of recurrence, improves central nervous system (CNS) DFS, and has a consistent safety profile in resected EGFR-mutated NSCLC.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Guang-Ling Jie, Lun-Xi Peng, Mei-Mei Zheng, Hao Sun, Song-Rong Wang, Si-Yang Maggie Liu, Kai Yin, Zhi-Hong Chen, Hong-Xia Tian, Jin-Ji Yang, Xu-Chao Zhang, Hai-Yan Tu, Qing Zhou, Catherine C. L. Wong, Yi-Long Wu
Summary: This study explores the clinical utility of plasma proteomics-derived biomarkers for MET-dysregulated NSCLC patients treated with MET inhibitors. Mass spectrometry analysis of longitudinal plasma samples revealed that the peripheral plasma proteomic characteristics were associated with treatment outcomes. A four-protein signature (MYH9, GNB1, ALOX12B, and HSD17B4) was identified as a high-accuracy predictor of response and progression-free survival in patients treated with MET inhibitors.
Article
Oncology
Yan Sun, Liang Zhu, Pian Liu, Huan Zhang, Feng Guo, Xin Jin
Summary: In this study, researchers found that the upregulation of palmitoyl acyltransferase ZDHHC2 is associated with TKI resistance in ccRCC. ZDHHC2 mediates AGK S-palmitoylation to activate the PI3K-AKT-mTOR signaling pathway, which modulates sunitinib sensitivity. These findings suggest that targeting ZDHHC2 may improve the efficacy of sunitinib in treating ccRCC.
Article
Multidisciplinary Sciences
Juliann Chmielecki, Tony Mok, Yi-Long Wu, Ji-Youn Han, Myung-Ju Ahn, Suresh S. Ramalingam, Thomas John, Isamu Okamoto, James Chih-Hsin Yang, Frances A. Shepherd, Krishna C. Bulusu, Gianluca Laus, Barbara Collins, J. Carl Barrett, Ryan J. Hartmaier, Vassiliki Papadimitrakopoulou
Summary: The third-generation EGFR tyrosine kinase inhibitor osimertinib improves progression-free survival compared to platinum-doublet chemotherapy in patients with advanced NSCLC carrying EGFR T790M mutation. In this study, the authors used next-generation sequencing to evaluate the potential mechanisms of acquired resistance to osimertinib in patients from the AURA3 trial. Some patients had undetectable plasma EGFR T790M at disease progression and/or treatment discontinuation.
NATURE COMMUNICATIONS
(2023)
Letter
Oncology
Ling Peng, Yawen Bin, Peng Ding, Lingjuan Chen, Hao Zeng, Zelong Xu, Liyan Ji, Xuan Gao, Pian Liu, Ye Wang, Sheng Zhang, Zhongxing Liao, Xuefeng Xia, Ruiguang Zhang, Fan Tong, Xiaorong Dong
CANCER COMMUNICATIONS
(2023)
Letter
Oncology
Si-Yang Maggie Liu, Cunte Chen, Yi-Kai Zhang, Wen-Zhao Zhong, Yi-Long Wu, Si-Yang Liu, Yangqiu Li
Summary: This study identified specific TCR sequences that can predict prognosis and favorable outcomes in EGFR-mutant NSCLC patients treated with adjuvant EGFR-TKI.
BIOMARKER RESEARCH
(2023)
Article
Oncology
Jhanelle E. Gray, Myung-Ju Ahn, Geoffrey R. Oxnard, Frances A. Shepherd, Fumio Imamura, Ying Cheng, Isamu Okamoto, Byoung Chul Cho, Meng-Chih Lin, Yi-Long Wu, Margarita Majem, Oliver Gautschi, Michael Boyer, Krishna C. Bulusu, Aleksandra Markovets, J. Carl Barrett, Rachel Hodge, Astrid Mckeown, Ryan J. Hartmaier, Juliann Chmielecki, Vassiliki A. Papadimitrakopoulou, Suresh S. Ramalingam
Summary: Plasma EGFRm analysis can predict the efficacy in EGFRm advanced NSCLC, especially when performed at around 3 weeks of treatment to predict the progression-free survival.
CLINICAL CANCER RESEARCH
(2023)
Article
Biochemistry & Molecular Biology
Lixin He, Jinxin Chen, Pinwei Deng, Shumei Huang, Pian Liu, Chanjuan Wang, Xinjian Huang, Yue Li, Boyu Chen, Dongni Shi, Yunyun Xiao, Xiangfu Chen, Ying Ouyang, Libing Song, Chuyong Lin
Summary: Cyst(e)ine plays a crucial role in the synthesis of glutathione and its storage in lysosomes helps cancer cells maintain redox homeostasis. Breast cancer cells upregulate MFSD12 to increase lysosomal cyst(e)ine storage, which is released to maintain GSH levels and buffer oxidative stress. mTORC1 regulates MFSD12 by phosphorylating residue T254, and this switch modulates lysosomal cyst(e)ine levels in response to oxidative stress, enhancing cell fitness. MFSD12 mutation inhibits its function and suppresses tumor progression, while its overexpression correlates with poor chemotherapy response and prognosis in breast cancer patients.
Article
Oncology
Haiqin Wang, Haohui Wang, Jiajing Chen, Pian Liu, Xiaoxiong Xiao
Summary: Studies have found that FAM111B is highly expressed in esophageal cancer tissues and promotes the progression of esophageal cancer cells by binding to GSDMA. The FAM111B/GSDMA axis also regulates the sensitivity of esophageal cancer to cisplatin. This discovery reveals a novel pathway that plays a significant role in esophageal cancer tumorigenesis and chemosensitivity.
Article
Oncology
Byoung Chul Cho, Myung-Ju Ahn, Jin Hyoung Kang, Ross A. Soo, Thanyanan Reungwetwattana, James Chih-Hsin Yang, Irfan Cicin, Dong-Wan Kim, Yi-Long Wu, Shun Lu, Ki Hyeong Lee, Yong-Kek Pang, Anastasia Zimina, Chin Heng Fong, Elena Poddubskaya, Ahmet Sezer, Soon Hin How, Pongwut Danchaivijitr, Yukyung Kim, Yeji Lim, Taewon An, Hana Lee, Hae Mi Byun, Bojan Zaric
Summary: Lazertinib demonstrated significant efficacy improvement compared with gefitinib in the first-line treatment of EGFR-mutated advanced NSCLC, with a manageable safety profile. The results of this study are of great importance for improving patient outcomes and guiding clinical practice.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Letter
Oncology
Roy S. Herbst, Yi-Long Wu, Masahiro Tsuboi
JOURNAL OF CLINICAL ONCOLOGY
(2023)